Aryx Therapeutics I
ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. The company uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of original drugs. Its products in clinical development portfolio include Tecarfarin (ATI-5923), an oral anticoagulant, which is in Phase III clinical development for the tre… Read more
Aryx Therapeutics I (ARYX) - Net Assets
Latest net assets as of September 2010: $-7.74 Million USD
Based on the latest financial reports, Aryx Therapeutics I (ARYX) has net assets worth $-7.74 Million USD as of September 2010.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.97 Million) and total liabilities ($13.71 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-7.74 Million |
| % of Total Assets | -129.52% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 44.1 |
Aryx Therapeutics I - Net Assets Trend (2005–2009)
This chart illustrates how Aryx Therapeutics I's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Aryx Therapeutics I (2005–2009)
The table below shows the annual net assets of Aryx Therapeutics I from 2005 to 2009.
| Year | Net Assets | Change |
|---|---|---|
| 2009-12-31 | $-2.92 Million | -110.64% |
| 2008-12-31 | $27.41 Million | -22.44% |
| 2007-12-31 | $35.35 Million | +137.72% |
| 2006-12-31 | $-93.71 Million | -39.69% |
| 2005-12-31 | $-67.09 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aryx Therapeutics I's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18710900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2009)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $28.00K | % |
| Other Components | $184.16 Million | % |
| Total Equity | $-2.92 Million | 100.00% |
Aryx Therapeutics I Competitors by Market Cap
The table below lists competitors of Aryx Therapeutics I ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Eastern Asteria Inc
PINK:EATR
|
$4.75 |
|
VBI Vaccines Inc.
NASDAQ:VBIVQ
|
$4.75 |
|
TERTIARY MINERALS - Frankfurt Stock Exchang
F:TMU
|
$4.75 |
|
KEDCO
STU:KEU
|
$4.76 |
|
WIJAYA KARYA (5AA.SG)
STU:5AA
|
$4.75 |
|
Air Berlin PLC
HM:AB1
|
$4.75 |
|
GOLDEN CROSS RES
MU:GCL
|
$4.74 |
|
BLUEPOOL (BPU.SG)
STU:BPU
|
$4.71 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aryx Therapeutics I's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2008 to 2009, total equity changed from 27,415,000 to -2,916,000, a change of -30,331,000 (-110.6%).
- Net loss of 33,167,000 reduced equity.
- Share repurchases of 92,000 reduced equity.
- Other comprehensive income decreased equity by 45,000.
- Other factors increased equity by 2,973,000.
Equity Change Factors (2008 to 2009)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-33.17 Million | -1137.41% |
| Share Repurchases | $92.00K | -3.16% |
| Other Comprehensive Income | $-45.00K | -1.54% |
| Other Changes | $2.97 Million | +101.95% |
| Total Change | $- | -110.64% |
Book Value vs Market Value Analysis
This analysis compares Aryx Therapeutics I's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-12-31 | $-22.52 | $0.00 | x |
| 2005-12-31 | $-73.72 | $0.00 | x |
| 2006-12-31 | $-92.06 | $0.00 | x |
| 2007-12-31 | $3.76 | $0.00 | x |
| 2008-12-31 | $1.45 | $0.00 | x |
| 2009-12-31 | $-0.11 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aryx Therapeutics I utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-31.97%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.08 Million |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $-21.26 Million |
| 2006 | 0.00% | -576.66% | 0.08x | 0.00x | $-17.96 Million |
| 2007 | -77.97% | -662.84% | 0.06x | 1.97x | $-31.10 Million |
| 2008 | -113.87% | -158.27% | 0.39x | 1.87x | $-33.96 Million |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-32.88 Million |
Industry Comparison
This section compares Aryx Therapeutics I's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aryx Therapeutics I (ARYX) | $-7.74 Million | 0.00% | N/A | $4.75 |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |